A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.
An 18-week, double-blind, crossover study of amantadine and neuroleptics in the treatment of tardive dyskinesia (TD) is described. A fixed-dose regimen was used, and objective rating scales for TD, extrapyramidal symptoms, and mental state were employed. The results indicate that amantadine is significantly better than placebo in the management of TD and that there is little risk of exacerbating psychosis. Further investigation of this potentially useful medication is warranted.
Angus
S
S
Raymond Care Centre, Provincial Mental Health Advisory Board, Alberta, Canada.
Sugars
J
J
Boltezar
R
R
Koskewich
S
S
Schneider
N M
NM
D000368:Aged; D000369:Aged, 80 and over; D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016001:Confidence Intervals; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D018709:Statistics, Nonparametric
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D000547:Amantadine